| scholarly article | Q13442814 |
| P50 | author | Simon C Watkins | Q87981821 |
| P2093 | author name string | David A Hokey | |
| Adriana T Larregina | |||
| Geza Erdos | |||
| Louis D Falo | |||
| P433 | issue | 21 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | dendritic cell | Q506253 |
| P304 | page(s) | 10059-10067 | |
| P577 | publication date | 2005-11-01 | |
| P1433 | published in | Cancer Research | Q326097 |
| P1476 | title | Tumor cell loaded type-1 polarized dendritic cells induce Th1-mediated tumor immunity | |
| P478 | volume | 65 |
| Q37808562 | Aerosol vaccines for tuberculosis: A fine line between protection and pathology |
| Q86710368 | Antitumor Responses Stimulated by Dendritic Cells Are Improved by Triiodothyronine Binding to the Thyroid Hormone Receptor β |
| Q45332420 | CISH is induced during DC development and regulates DC‐mediated CTL activation |
| Q38015631 | Cancer therapy and vaccination |
| Q38840254 | Coley's Lessons Remembered: Augmenting Mistletoe Therapy |
| Q30357322 | DNA vaccines for HIV: challenges and opportunities. |
| Q43678721 | Deletion of RBP-J in dendritic cells compromises TLR-mediated DC activation accompanied by abnormal cytoskeleton reorganization |
| Q34649397 | Dendritic cells in cancer immunotherapy: vaccines and combination immunotherapies. |
| Q37960189 | Developing dendritic cell-based therapies to condition immune responses to novel oncogenic proteins and stem cells |
| Q80466965 | Downregulation of CD4+CD25+ regulatory T cells may underlie enhanced Th1 immunity caused by immunization with activated autologous T cells |
| Q33744525 | Effective immunotherapy against murine gliomas using type 1 polarizing dendritic cells--significant roles of CXCL10. |
| Q83513978 | Enhancement of protective immunity against intracellular bacteria using type-1 polarized dendritic cell (DC) vaccine |
| Q36345439 | Gene therapy-mediated reprogramming tumor infiltrating T cells using IL-2 and inhibiting NF-κB signaling improves the efficacy of immunotherapy in a brain cancer model |
| Q37173478 | Generation in vivo of peptide-specific cytotoxic T cells and presence of regulatory T cells during vaccination with hTERT (class I and II) peptide-pulsed DCs. |
| Q36469826 | Heterologous prime/boost immunization with p53-based vaccines combined with toll-like receptor stimulation enhances tumor regression. |
| Q57476065 | Hydrophilic Astragalin Galactoside Induces T Helper Type 1-Mediated Immune Responses via Dendritic Cells |
| Q84062498 | IL-32γ Induces the Maturation of Dendritic Cells with Th1- and Th17-Polarizing Ability through Enhanced IL-12 and IL-6 Production |
| Q38912259 | Implications of chemokine receptors and inflammatory lipids in cancer |
| Q42261479 | Increased extracellular pressure provides a novel adjuvant stimulus for enhancement of conventional dendritic cell maturation strategies |
| Q40167750 | Induction of immunity to neuroblastoma early after syngeneic hematopoietic stem cell transplantation using a novel mouse tumor vaccine |
| Q39547016 | Modification of Human Embryonic Stem Cell-Derived Dendritic Cells with mRNA for Efficient Antigen Presentation and Enhanced Potency |
| Q34916497 | Monocyte-derived DC maturation strategies and related pathways: a transcriptional view |
| Q84582609 | Multi-Compartmental Vaccine Delivery System for Enhanced Immune Response to gp100 Peptide Antigen in Melanoma Immunotherapy |
| Q36761540 | Neurokinin-1 receptor agonists bias therapeutic dendritic cells to induce type 1 immunity by licensing host dendritic cells to produce IL-12 |
| Q37461365 | Novel strategies for improved cancer vaccines |
| Q37513293 | Optimization of dendritic cell loading with tumor cell lysates for cancer immunotherapy |
| Q42256888 | PGE2-induced IDO1 inhibits the capacity of fully mature DCs to elicit an in vitro antileukemic immune response |
| Q37735454 | Polarized dendritic cells as cancer vaccines: directing effector-type T cells to tumors |
| Q37000845 | Potent tumor-specific protection ignited by adoptively transferred CD4+ T cells |
| Q37143656 | Proinflammatory tachykinins that signal through the neurokinin 1 receptor promote survival of dendritic cells and potent cellular immunity |
| Q48219588 | Promoting the accumulation of tumor-specific T cells in tumor tissues by dendritic cell vaccines and chemokine-modulating agents. |
| Q26849305 | Regulation of immune responses by prostaglandin E2 |
| Q36914835 | TLR-mediated induction of negative regulatory ligands on dendritic cells |
| Q37461812 | TLR3-stimulated dendritic cells up-regulate B7-H1 expression and influence the magnitude of CD8 T cell responses to tumor vaccination |
| Q48351056 | The intravenous anesthetic propofol inhibits human L-type calcium channels by enhancing voltage-dependent inactivation. |
| Q55430751 | The systemic evaluation and clinical significance of immunological function for advanced lung cancer patients |
| Q36391595 | Tumor-Derived Autophagosome Vaccine: Mechanism of Cross-Presentation and Therapeutic Efficacy |
| Q34009362 | Type-1 polarized dendritic cells primed for high IL-12 production show enhanced activity as cancer vaccines |
| Q39768767 | Vaccines using dendritic cells, differentiated with propofol, enhance antitumor immunity in mice |
Search more.